


(図1 続き)



(図1 続き)




表1 感染者数など

	SV2% <sup>@0</sup>	UV2% <sup>@0</sup>	UV2% <sup>@12</sup>	SV8% <sup>@0</sup>	UV8% <sup>@0</sup>	UV8% <sup>@12</sup>
感染者 (垂直感染は除く)	58,769	23,165	22,236	58,899	44,647	32,963
AH	5,865	2,301	2,219	5,878	4,446	3,283
持続性感染	2,710	1,041	1,068	2,718	2,005	1,550
垂直感染	98	98	98	98	98	98
AH→FH	376	147	138	377	282	206
AH→CH	55	22	17	55	46	40
HBeAg→CH	275	108	110	275	204	148
HBeAg→HCC	300	111	112	300	216	167
HBeAb→CC	297	97	113	297	183	139
HBeAb→HCC	75	30	34	75	56	36
CH→CC	89	29	27	90	60	56
CH→HCC	0	0	0	0	0	0
CC→DC	123	42	50	124	80	57
CC→HCC	139	49	56	140	92	69
DC→HCC	72	23	26	72	44	33
FH→Death	218	80	78	219	172	128
DC→Death	21	0	0	21	11	0
HCC→Death	537	194	216	538	374	284
CC	386	126	140	387	243	195
DC	123	42	50	124	80	57
HCC	586	213	228	587	408	305

図2 新規感染者




図3 累積感染者




図4 非代償性肝硬変（累積）




図5 肝がん（累積）




図7 肝がんによる死亡（累積）




表2 費用対効果分析の結果

Discount Factor	ワクチン効果 通過率	cost(¥)			effectiveness(QALYs)			net benefit(¥)			ICER(¥)	
		SV	UV@0	UV@12	SV	UV@0	UV@12	SV	UV@0	UV@12	SV→UV@0	SV→UV@12
0	0.02	9,252	16,251	14,168	72.0909	72.1053	72.1047	360,445,248	360,510,249	360,509,332	486,042	356,232
	0.08	9,272	19,346	15,537	72.0909	72.0979	72.1019	360,445,228	360,470,154	360,493,963	1,439,143	569,545
	0.02	2,807	13,736	8,493	30.0486	30.0517	30.0516	150,240,193	150,244,764	150,249,507	3,525,484	1,895,333
0.03	0.08	2,812	14,594	8,814	30.0486	30.0502	30.0511	150,240,188	150,236,406	150,246,686	7,363,750	2,400,800
	0.02	1,499	13,253	6,490	20.246	20.2474	20.2473	101,228,501	101,223,747	101,230,010	8,395,714	3,839,231
	0.08	1,501	13,663	6,623	20.246	20.2467	20.2471	101,228,499	101,219,837	101,228,877	17,374,286	4,656,364
0.068	0.02	947	13,058	5,215	15.4866	15.4872	15.4872	77,432,053	77,422,942	77,430,785	20,185,000	7,113,333
	0.08	949	13,283	5,280	15.4866	15.4869	15.4871	77,432,051	77,421,217	77,430,220	41,113,333	8,662,000

図8 接種政策の関係と評価

